Home / Science / New Blood Test Predicts Alzheimer's Decline
New Blood Test Predicts Alzheimer's Decline
19 Nov
Summary
- Blood test detects protein linked to Alzheimer's disease.
- Test could predict cognitive decline 5-10 years in advance.
- Older age significantly increases risk at same test level.

A groundbreaking blood test has shown promise in predicting cognitive decline associated with Alzheimer's disease up to a decade in advance. Researchers at Mayo Clinic published findings in JAMA Neurology indicating that measuring levels of phosphorylated tau 217 (p-tau217) in the blood can help identify individuals at higher risk. The study involved over 2,000 cognitively unimpaired adults aged 60 to 90.
While the presence of the APOE ε4 genetic variant and older age were associated with increased risk, the p-tau217 blood biomarker proved to be a significant predictor. The findings highlight that even at the same p-tau217 level, an 85-year-old faces a substantially higher predicted risk of mild cognitive impairment compared to a 65-year-old.
This less invasive blood test could offer a more scalable alternative to PET scans for assessing Alzheimer's-related pathology. Researchers emphasize that the test's full significance will be realized if effective preventive treatments become available, enabling more informed discussions between patients and clinicians about potential interventions.
However, the research team cautions that the risk prediction model, developed using data from southeast Minnesota, requires replication in diverse populations. The test is not yet recommended for routine screening of asymptomatic individuals, as no approved treatments exist to alter the course of the disease in such cases.